Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 17, 2024 12:25pm

136 Views

Post# 35885871

RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)

In October 2023 ONCY data from the PDAC arm of the GOBLET study (pelareorep + immune checkpoint inhibitor - atezolizumab), was presented showing a 62% objective response rate (ORR), 7.2 months of median progression-free survival (mPFS), interim median overall survival (mOS) of 10.6 months, and expansion of both pre-existing and new T-cell clones.

Analysis of changes of T-cell clones and tumor-infiltrating lymphocytes (TILs) showed:

- - Mean baseline TIL cell levels of 22%
- - Expansion of pre-existing and new T cell clones, including the expansion of TIL-specific clones
- - A correlation between the expansion in the blood of TIL-specific clones and tumor response

https://oncolyticsbiotech.com/press_releases/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-1-2-study-at-esmo/